Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Sep;66(3):411-3.
doi: 10.1111/j.1365-2125.2008.03172.x. Epub 2008 Jul 15.

Effect of atorvastatin on hs-CRP in acute coronary syndrome

Ankur Gupta  1 , Dinesh K Badyal, Prem P Khosla, Bharti Uppal, Thannikot M Jaison, Sandeep Chopra
Affiliations

Effect of atorvastatin on hs-CRP in acute coronary syndrome

Ankur Gupta et al. Br J Clin Pharmacol. 2008 Sep.

Abstract

Aims: To evaluate the effect of a lower dose (20 mg) of atorvastatin on hs-CRP concentrations in patients with ACS.

Methods: Group A (n = 50) patients received atorvastatin 20 mg day(-1) for 4 weeks in addition to standard anti-anginal treatment. Group B (n = 50) patients received standard anti-anginal treatment without atorvastatin.

Results: hs-CRP concentrations decreased in both groups, but the decrease was greater in group A. The decrease in hs-CRP was also significantly greater in the subgroups of smoking, hypertension and past history of cardiovascular disease with atorvastatin.

Conclusions: The use of a lower dose (20 mg) of atorvastatin can offer an attractive approach for early treatment of patients with ACS.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean percentage decrease in plasma hs-CRP in the subgroups. Group A Atorvastatin, (formula image); Group B Without atorvastatin, (formula image)
See this image and copyright information in PMC

References

    1. Blake GJ, Ridker PM. CRP and other inflammatory markers in acute coronary syndromes. J Am Coll Cardiol. 2003;41:375–425. - PubMed
    1. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T. Effect of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. J Am Med Assoc. 2001;285:1711–8. - PubMed
    1. Jialal I, Stein D, Balis D, Grundy SM, Adams Heut B, Devaraj S. Effect of HMG-CoA reductase inhibitor therapy on high sensitivity CRP levels. Circulation. 2001;103:1933–5. - PubMed
    1. Patel TN, Shishehbor MH, Bhatt DL. A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis. Eur Heart J. 2007;28:664–72. - PubMed
    1. Papathanasiou AI, Pappas KD, Korantzopoulus P, Leontaridis JP, Vougiouklakis TG, Kiriou M, Dimitroula V, Michalis LK, Goudevenos JA. An epidemiological study of acute coronary syndromes in north western Greece. Angiology. 2004;55:187–94. - PubMed

MeSH terms